Heartware to lodge prospectus despite litigation rumours

By Renate Krelle
Friday, 17 December, 2004

US artificial heart firm Heartware will today lodge its prospectus with ASIC, for an ASX-listing schedule to take place in late January, despite rumours of a possible patent battle with Australian artificial heart firm Ventracor (ASX:VCR).

The offer incorporates an AUD$5 million US private placement together with an Australian public offer to make up a combined capital raising of US$24.95 million. The Australian offer -- at $0.50 per share -- will raise between AUD$30 and AUD$35 million, subject to the exchange rate at the day of allotment.

The offer will open on December 29 and close on January 19. The listing is scheduled to take place on January 31.

The 'risks' section of the prospectus is said to outline a patent issue between Ventracor and Heartware. The company did not respond to Australian Biotechnology News' requests for further details.

The Heartware ventricular assist device is one third of the size of Ventracor's VentrAssist, and is placed in the pericardial space directly adjacent to the heart.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd